OncoMatch/Clinical Trials/NCT05445310
Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer
Is NCT05445310 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Furmonertinib for non-small cell lung cancer.
Treatment: Furmonertinib — This is a prospective, single arm study to investigate the efficacy and safety furmonertinib 80mg/d as adjuvant treatment for 3 years post surgery of stage IA with high-risk factors and stage IB non-small cell lung cancer. A total of 114 patients would be enrolled. The primary endpoint is the disease-free survival rate at 3 years.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR exon 19 deletion
EGFR mutation positive according to NGS testing by tissue, including deletions in exon 19, L858R, S768I, G719X, L861Q, T790M mutations et al.
Required: EGFR L858R
EGFR mutation positive according to NGS testing by tissue, including deletions in exon 19, L858R, S768I, G719X, L861Q, T790M mutations et al.
Required: EGFR S768I
EGFR mutation positive according to NGS testing by tissue, including deletions in exon 19, L858R, S768I, G719X, L861Q, T790M mutations et al.
Required: EGFR G719X
EGFR mutation positive according to NGS testing by tissue, including deletions in exon 19, L858R, S768I, G719X, L861Q, T790M mutations et al.
Required: EGFR L861Q
EGFR mutation positive according to NGS testing by tissue, including deletions in exon 19, L858R, S768I, G719X, L861Q, T790M mutations et al.
Required: EGFR T790M
EGFR mutation positive according to NGS testing by tissue, including deletions in exon 19, L858R, S768I, G719X, L861Q, T790M mutations et al.
Excluded: EGFR exon 20 insertion
EGFR exon 20 insertion positive [excluded].
Excluded: ALK alteration
Concurrent with other diver mutations including alterations in ALK, ROS1, MET et al.
Excluded: ROS1 alteration
Concurrent with other diver mutations including alterations in ALK, ROS1, MET et al.
Excluded: MET alteration
Concurrent with other diver mutations including alterations in ALK, ROS1, MET et al.
Disease stage
Required: Stage IA, IB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: surgery — radical resection
Received radical resection of non-small cell lung cancer
Cannot have received: radiotherapy
without prior anti-tumor therapies including radiotherapy, chemotherapy, target therapy and immunotherapy
Cannot have received: chemotherapy
without prior anti-tumor therapies including radiotherapy, chemotherapy, target therapy and immunotherapy
Cannot have received: targeted therapy
without prior anti-tumor therapies including radiotherapy, chemotherapy, target therapy and immunotherapy
Cannot have received: immunotherapy
without prior anti-tumor therapies including radiotherapy, chemotherapy, target therapy and immunotherapy
Lab requirements
Blood counts
sufficient organ function in hematology
Kidney function
sufficient organ function in renal, kidney
Liver function
sufficient organ function in liver
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify